Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCA-derived mesenchymal stromal cells
- Development stage
- Unknown
- Lead developer
- Leiden University Medical Center
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
MCA-derived mesenchymal stromal cells (MSCs) are a specific preparation of mesenchymal stromal cells developed by the Leids Universitair Medisch Centrum (LUMC) for use in regenerative medicine and immunology. In the context of renal transplantation, these cells are being investigated for their immunomodulatory properties to prevent or treat biopsy-proven acute rejection. Mesenchymal stromal cells are known to exert anti-inflammatory effects by secreting various cytokines and interacting with immune cells such as T cells, B cells, and dendritic cells, thereby promoting a pro-tolerogenic environment. The 'MCA' designation likely refers to a specific manufacturing protocol or source used by the LUMC facility. A Phase 3 clinical trial (EU CTIS 2024-512553-25-00) is evaluating this therapy in renal transplant recipients to improve graft survival and reduce the need for intensive immunosuppression.
- Other names
- MCA-derived mesenchymal stromal cellsMCA-derived MSC therapy
Beyond the preview
Go deeper on MCA-derived mesenchymal stromal cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MCA-derived mesenchymal stromal cells.